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ABSTRACT 
Effective delivery of drugs to colon is a challenge, as the drug needs to be protected from gastrointestinal environment and should be 
released intact in colon.  Present study is aimed to develop a site-specific nanoparticulate formulation containing herbal anti-cancer 
agent in treatment of colon cancer. The Diallyl disulfide nanoparticles (DADS-NPs) were prepared by nanoprecipetation method and 
optimized formulation was selected using Box-Behnken design (BBD). The particle size of NPs was found to be 108 nm. The 
encapsulation efficiency was found to be 77.24%. and in-vitro release data has revealed controlled and prolonged drug release up to 
72h. 
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INTRODUCTION: 
Targeted drug delivery systems provides medication 
intact to   targeted site  by  improving  its safety, 
efficacy and lowering the frequency of dose, due to 
which there has been increased interest in formulation of 
site-specific drug delivery system. Colon-specific drug 
delivery systems can be advantageous to target the drugs 
directly to the colon in malignancies like cancer of colon 
and rectum. This site-specific drug delivery system can 
achieve high concentration of drugs in colon to improve 
its bioavailability and to lower its systemic toxicity. The 
potential of DADS as an anticancer agent in colon 
cancer has extensively been investigated. The present 
study is aimed to develop a nano-particulate drug 
delivery system containing a herbal anti-cancer agent, 
Diallyldisulfide, for colorectal cancer cells as they show 
enhanced permeation, accumulation and retention in the 
tumor tissue
1
. 
MATERIAL AND METHODS: 
Material 
PLGA (75:25) was obtained as gift sample from 
Corbion Purac (Netherlands). DADS were procured 
from Sigma Aldrich. All other chemicals and reagents 
were of analytical grade. 
Method 
The DADS loaded nanoparticles were prepared by 
nanoprecipitation method using acetone as a solvent. 
Briefly, PLGA (75:25) and DADS were dissolved in 5 
ml of acetone. The prepared solution was added drop-
wise with syringe (G¼22) into 20 ml of distillated water 
under magnetic stirrer at room temperature. The 
resulting solution was stirred for complete evaporation 
of the organic solvent. The nanoparticles were collected 
by centrifugation and further freeze dried. The effect of  
independent variables viz. change in stirring speed, 
polymer to drug ratio, ratio of volume of outer water 
phase to the organic phase and concentration of 
surfactant was studied  on particle size and entrapment 
efficiency(dependent variables). The optimized 
formulation was selected by application of Box Behnken 
design using Design expert software.  
RESULTS AND DISCUSSION: 
A Box-Behnken design was applied for optimization of 
NPs formulation. The optimized formulation of NPs  
were selected on the basis of criteria of attaining the 
maximum value of encapsulation efficiency while 
minimizing the particle size with numerical point 
prediction optimization method using Design Expert 
software®. Scanning electron microscopic images have 
showed that the nanoparticles have regular and uniform 
shape (Figure 1). The average particle size of 
nanoparticles was found to be 108nm. The zeta potential 
of NPs were found to be + 31.5mV ± 2mV, which 
indicated the physical stability of the formulation. The 
value of polydispersity index was found to be 0.206. 
The optimized formulation has shown entrapment 
efficiency of 77.24%. The in-vitro drug release have 
shown initial burst release and then prolonged drug 
Saraf et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2017; 7(7):50-51                       
ISSN: 2250-1177                                                                                [51]                                                                             CODEN (USA): JDDTAO 
release with cumulative drug release of 74.54%. The 
release kinetics was studied by applying zero order 
kinetic model, first order kinetic model, Higuchi model 
and Korsmeyer-Peppas. According to the highest 
correlation (R
2
) value it is evident that the optimized 
formulation of DADS nanoparticles follows the Higuchi 
model.  
 
Figure 1: Scanning electron microscopic image of 
nanoparticles 
 
Figure 2: Drug release kinetics of nanoparticles 
CONCLUSION: 
The result of the study has shown physical stability, 
good encapsulation efficiency and prolonged rate of 
drug release from nanoparticles. Thus, it can be 
concluded that the PLGA nanoparticles containing 
DADS could provide a promising strategy for treatment 
of colon cancer with enhanced bioavailability with 
further cytotoxicity and in-vivo studies. 
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